Skip to content

Comparison of Intertransverse Process and Erector Spinae Plane Blocks in Acute Postoperative Analgesia Management for Laparoscopic Cholecystectomy Patients

Comparison of Intertransverse Process and Erector Spinae Plane Blocks in Acute Postoperative Analgesia Management for Laparoscopic Cholecystectomy Patients: A Multicenter Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07504705
Enrollment
110
Registered
2026-04-01
Start date
2026-05-01
Completion date
2027-05-25
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acut Postoperative Pain, Erector Spinae Plane Block, Intertransverse Process Block

Keywords

Laparoscopic Cholecystectomy, Erector Spinae Plane Block, Intertransverse Process Block, Postoperative Pain

Brief summary

Laparoscopic cholecystectomy is considered the gold standard for the surgical treatment of benign gallbladder diseases; however, despite its minimally invasive nature, a significant proportion of patients experience substantial early postoperative pain, which impacts patient comfort and the duration of hospital stay. The current PROSPECT review and previous studies emphasize that this pain is multifactorial-comprising somatic, visceral, and phrenic nerve-mediated shoulder-tip components-and therefore advocate for an opioid-sparing multimodal analgesic approach. Within this framework, first-line recommendations include paracetamol, NSAIDs/COX-2 inhibitors, dexamethasone, and local anesthetic infiltration of the surgical site and/or intraperitoneal cavity, alongside appropriate regional blocks; opioids should be reserved solely for rescue analgesia \[1-3\]. Ultrasound-guided regional anesthesia blocks are increasingly utilized for acute visceral pain conditions, such as renal colic \[4\]. The Erector Spinae Plane Block (ESPB) is an interfacial block performed in the thoracic paraspinal region, and it is hypothesized that its extensive spread may influence somatic and, to some extent, visceral pain pathways \[5\]. Nevertheless, anatomical and clinical studies report inconsistent effects of ESPB on visceral pain, noting that local anesthetics may not consistently reach the paravertebral space, thereby leading to variable block efficacy \[6,7\]. Consequently, the Intertransverse Process Block (ITPB), which targets a plane anatomically closer to the paravertebral space, has been described in recent years as an alternative technique. ITPB is performed by injecting local anesthetic into the interfacial space adjacent to the retro-superior costotransverse ligament; it is reported to carry a low risk of complications as it does not require direct orientation toward the pleura or neuraxial structures \[8\]. Clinical trials indicate that ITPB provides analgesic efficacy comparable to paravertebral blocks in both thoracic and abdominal surgeries and reduces opioid consumption \[9\]. Furthermore, anatomical studies suggest that the probability of local anesthetic spread into the paravertebral space is higher with ITPB than with ESPB \[10\]. However, a randomized controlled trial comparing ESPB and ITPB in patients undergoing laparoscopic cholecystectomy is currently lacking in the literature. Therefore, the present study was designed to address this gap.

Interventions

The ITPB will be performed using the same ultrasound (US) device. Initially, the spinous process of the T8 vertebra will be visualized in the horizontal plane at the midline using a linear probe. The probe will then be shifted approximately 2 cm laterally to the right and left of the midline in the longitudinal plane to visualize the superior costotransverse ligament (SCTL) spanning between the transverse processes and the pleura. The block needle will be advanced in-plane in a caudal-to-cranial direction, parallel to the SCTL, and stopped just before reaching the cranial aspect of the eighth rib. After the space is confirmed via hydrodissection, 20 mL of 0.375% bupivacaine (not exceeding a maximum dose of 2.5 mg/kg) will be injected without penetrating the SCTL, while simultaneously monitoring the volume spread via US. The block will be performed unilaterally at the level of the right hemithorax.

PROCEDUREErector Spinae Plane Block

The ESPB will be performed in the sitting position under ultrasound (US) guidance using a 6-10 MHz linear ultrasound probe (Mindray DC-60 Exp; Mindray Bio-Medical Electronics, Shenzhen, China). The transverse process and erector spinae muscles at the T8 level will be visualized in a longitudinal parasagittal plane. An echogenic 22 G, 80 mm needle (Stimuplex A, B. Braun, Melsungen, Germany) will be advanced in-plane in a caudal-to-cranial direction until contact is made with the transverse process beneath the erector spinae muscle. Following negative aspiration, 20 mL of 0.5% bupivacaine will be injected, ensuring visualization of the spread within the fascial plane. The block will be performed unilaterally on the right hemithorax.

Sponsors

Konya City Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Eligible patients will be allocated into two groups-the ITPB group and the ESPB group-in a 1:1 ratio. Randomization will be performed using a computer-generated algorithm with variable block sizes (4-8). The randomly generated codes will be maintained by non-study personnel and will remain inaccessible to the investigators. The randomization sequence will be placed in sequentially numbered, opaque, sealed envelopes by a staff member not involved in the study. Through this methodology, triple-blinding will be ensured: the patient, the outcome assessor, and the data analyst will remain blinded to the group allocation.

Intervention model description

Participants will be randomized into two parallel groups to receive either an ultrasound-guided intertransverse process block (ITPB) or an erector spinae plane block (ESPB). Each participant will receive only one intervention, and postoperative outcomes will be compared between the two groups. This study aims to provide a 'head-to-head' comparison between these two active regional anesthesia techniques.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Undergoing elective laparoscopic cholecystectomy Body mass index (BMI) between 18 and 35 kg/m² American Society of Anesthesiologists (ASA) physical status score of I-III Ability to provide written and verbal informed consent

Exclusion criteria

Coagulopathy or use of anticoagulant medications Infection at the injection site Allergy to local anesthetics Pregnancy or breastfeeding Chronic opioid use or analgesic dependence Severe cardiopulmonary disease or psychiatric disorders Previous regional block performed within the last 24 hours Patients requiring emergency surgery Cases converted from laparoscopic surgery to open surgery

Design outcomes

Primary

MeasureTime frameDescription
NRS Score0 to 24 hours postoperativelyThe primary objective of this study is to compare the effects of ESPB and ITPB techniques on Numeric Rating Scale (NRS) pain scores in patients undergoing laparoscopic cholecystectomy. Our hypothesis is that NRS scores will be lower in patients receiving ITPB compared to the ESPB group, as the ITPB is expected to provide more extensive visceral analgesia.

Secondary

MeasureTime frameDescription
Opioid consumption0 to 24 hours postoperativelyThe secondary objective of the study is to evaluate the effects of ESPB and ITPB on opioid consumption. The amounts of rescue analgesic (tramadol) administered in the post-block period will be recorded. Our hypothesis is that opioid requirements will be lower in patients receiving ITPB compared to the ESPB group, due to the provision of more effective analgesia.

Countries

Turkey (Türkiye)

Contacts

CONTACTÖmer Keklicek, Principal Investigator
drokeklicek@gmail.com+905399291702

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026